These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2421 related articles for article (PubMed ID: 30586774)

  • 41. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Stone NJ; Robinson JG; Lichtenstein AH; Bairey Merz CN; Blum CB; Eckel RH; Goldberg AC; Gordon D; Levy D; Lloyd-Jones DM; McBride P; Schwartz JS; Shero ST; Smith SC; Watson K; Wilson PW;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt B):2889-934. PubMed ID: 24239923
    [No Abstract]   [Full Text] [Related]  

  • 42. AHA/ACC/Multisociety Cholesterol Guidelines: highlights.
    Jialal I; Devaraj S
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719881579. PubMed ID: 31590600
    [No Abstract]   [Full Text] [Related]  

  • 43. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Reboussin DM; Allen NB; Griswold ME; Guallar E; Hong Y; Lackland DT; Miller EPR; Polonsky T; Thompson-Paul AM; Vupputuri S
    J Am Coll Cardiol; 2018 May; 71(19):2176-2198. PubMed ID: 29146534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 46. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.
    ; Drozda JP; Ferguson TB; Jneid H; Krumholz HM; Nallamothu BK; Olin JW; Ting HH; ; Heidenreich PA; Albert NM; Chan PS; Curtis LH; Ferguson TB; Fonarow GC; Ho PM; O'Brien S; Russo AM; Thomas RJ; Ting HH; Varosy PD
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):68-95. PubMed ID: 26666514
    [No Abstract]   [Full Text] [Related]  

  • 48. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.
    ; Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Covington AM; DePalma SM; Minissian MB; Orringer CE; Smith SC; Waring AA; Wilkins JT
    J Am Coll Cardiol; 2022 Oct; 80(14):1366-1418. PubMed ID: 36031461
    [No Abstract]   [Full Text] [Related]  

  • 49. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
    Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
    Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Reboussin DM; Allen NB; Griswold ME; Guallar E; Hong Y; Lackland DT; Miller EPR; Polonsky T; Thompson-Paul AM; Vupputuri S
    Hypertension; 2018 Jun; 71(6):e116-e135. PubMed ID: 29133355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
    Lee S; Cannon CP
    Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
    Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
    JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
    Virani SS; Newby LK; Arnold SV; Bittner V; Brewer LC; Demeter SH; Dixon DL; Fearon WF; Hess B; Johnson HM; Kazi DS; Kolte D; Kumbhani DJ; LoFaso J; Mahtta D; Mark DB; Minissian M; Navar AM; Patel AR; Piano MR; Rodriguez F; Talbot AW; Taqueti VR; Thomas RJ; van Diepen S; Wiggins B; Williams MS;
    Circulation; 2023 Aug; 148(9):e9-e119. PubMed ID: 37471501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
    Tokgözoğlu L; Casula M; Pirillo A; Catapano AL
    Atheroscler Suppl; 2020 Dec; 42():e1-e5. PubMed ID: 33589218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M;
    Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines.
    Nayor M; Vasan RS
    Circulation; 2016 May; 133(18):1795-806. PubMed ID: 27143546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
    Last AR; Ference JD; Menzel ER
    Am Fam Physician; 2017 Jan; 95(2):78-87. PubMed ID: 28084704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future.
    Stone NJ; Grundy SM
    Prog Cardiovasc Dis; 2019; 62(5):375-383. PubMed ID: 31733217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 122.